Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › Eli Lilly, Zentalis Pharma Partner to Study Selective Estrogen Receptor Degrader, Verzenio Combo

Eli Lilly, Zentalis Pharma Partner to Study Selective Estrogen Receptor Degrader, Verzenio Combo

Jul 27, 2020
|
staff reporter

NEW YORK – Clinical-stage biopharmaceutical company Zentalis Pharmaceuticals said on Monday that it is partnering with Eli Lilly to evaluate Zentalis' ZN-c5, an investigational oral selective estrogen receptor degrader (SERD), in combination with Lilly's CDK4/6 inhibitor abemaciclib (Verzenio), in patients with estrogen receptor-positive, HER2-negative, advanced breast cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
23
Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
25
Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Apr
08
Featured Webinar

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

What's Popular?

In Cancer

  1. Elicio Therapeutics Sharpens Development Plan for Cancer Vaccine in KRAS-Mutated Tumors

    Premium

  2. CHMP Recommends Approval of GSK's Dostarlimab in Endometrial Cancer

  3. Novartis Licenses BeiGene's Anti-PD-1 Agent Tislelizumab in North America, Europe, Japan

  4. Cartesian Therapeutics Bets on mRNA Engineering for Moving CAR T Cells Into Frontline Treatment

    Premium

  5. In Brief This Week: Kura Oncology, Innovent Biologics, Iaso Biotherapeutics, Invitae, Hologic

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.